The U.S. Food and Drug Administration (FDA) has given a fast track designation to CB-011, an experimental CAR T-cell therapy being developed by Caribou Biosciences for people with relapsed or refractory multiple myeloma. Fast track status is given to investigational treatments with the potential to fill an…
More than a dozen new mouse models of multiple myeloma, which researchers hope will advance understanding and treating the disease, were described in a new study. “We have generated artificial mice that accurately reflect key aspects of the origin and development of multiple myeloma in humans,” Marta Larráyoz, the…
ISB 1442, Ichnos Sciences’ investigational bi-specific antibody-based treatment, has earned orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma. The designation is awarded to therapies that show promise for rare diseases, those affecting fewer than 200,000 people in the U.S.
Multiple myeloma patients in the U.S. will now have access to Rapid Novor‘s noninvasive and highly sensitive blood test for monitoring minimal residual disease activity, or the small number of cancer cells that remain in a patient’s body after treatment. The test, called EasyM, previously was…
Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for multiple myeloma, a new study shows. “We’ve found that blocking the FABPs can prevent the growth of myeloma cells, mainly by slowing the cells’ proliferation [growth rate],” Michaela Reagan,…
Janssen and radio host and comedian D.L. Hughley are partnering to call attention to multiple myeloma in Black communities, with a goal of driving better patient outcomes. The national campaign, “That’s My Word,” will provide information and resources specifically for African Americans — who are at a…
For this Myeloma Action Month (MAM), observed each March to call attention to multiple myeloma and those affected by the blood disorder, the International Myeloma Foundation (IMF) is focusing on telling the myeloma community’s stories. The global event is aimed at heightening awareness of myeloma, which accounts…
The U.S. Food and Drug Administration (FDA) has granted priority review to Pfizer‘s application of its investigational under-the-skin therapy elranatamab for people with relapsed or refractory multiple myeloma. Priority review is given to therapies that target serious medical conditions that outperform current treatments to make them available to…
The U.S. Food and Drug Administration (FDA) has granted fast track and regenerative medicine advanced therapy designations to CT103A, IASO Biotherapeutics’ experimental CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), the company announced. These statuses complement the orphan drug designation the treatment received from the regulatory…
Abecma (idecabtagene vicleucel or ide-cel) reduced the risk of disease progression or death by half in adults with relapsed or refractory multiple myeloma (RRMM) who’d received two to four therapies without responding to the last one. That’s according to full results of the Phase 3 KarMMa-3 clinical…
Get regular updates to your inbox.